Key result
Case report estimates economic costs of nicotine use and treatment at tertiary hospitals during COVID-19.
Why the study?
There is hardly any data regarding the economic impact of tobacco use during the COVID-19 pandemic.
Case Report (n=1)
This case report highlights the economic burden and treatment expenditure associated with nicotine dependence during the COVID-19 pandemic.
Tobacco's psychiatric risks persist amid COVID-19; leaves open targeted interventions in affected populations.
Tobacco kills more than 8 million people globally every year. Tobacco adversely affects the individual and family, adding to the economic burden. More than 7 million deaths are directly related to nicotine use and around 1.2 million are due to passive smoking, which is exposure by nonsmokers. Tobacco smoking is a known risk factor for numerous physical health diseases particularly respiratory diseases and psychiatric conditions. COVID-19 pandemic has caused an additional burden on people’s health and economic life across the world. There is hardly any data about the economic impact of tobacco use during the pandemic. Here, we report a case to estimate the economic cost of nicotine use during COVID-19 and treatment expenditure at tertiary care hospitals.
No takes yet. Share an insight, caveat, or question.
M Kishor (2022) conducted a case report in Nicotine dependence during COVID-19 (n=1). Nicotine use was evaluated on Economic cost of nicotine use and treatment expenditure. A case report was presented to estimate the economic cost of nicotine use and treatment expenditure at tertiary care hospitals during the COVID-19 pandemic.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More from Journal of Psychiatry Spectrum